As part of the fringe event programme for this year’s One Nucleus Genesis conference being held in London on 11th December, Emirates are proud to present a seminar on “Logistics for Clinical Trials” at the Radisson Blu Hotel at London Stansted Airport on the evening of 12th December from 17.30-20.30.

This event is being held in partnership with the M11 Health Enterprise Forum and Invest ESSEX. Click here to register.

The growth of logistics for clinical trials

The world’s pharma companies spend $71 billion a year on research and development for biopharma products. At present there are approximately 7,000 medicines, globally, undergoing the clinical trials process as part of their R&D.

Most experts estimate that logistics for clinical trials accounts for 20 – 25% of total R&D costs. There is evidence that this share is growing; a recent report by EvaluatePharma reports that logistics services for clinical trials are growing at 12% per annum, which is faster than the overall R&D market growth of 2 – 2.5%. More and more clinical trials are taking place in Asia, Africa, and the Middle East.

Funders, whether shareholders, governments or grant awarding institutions are increasingly putting pressure on those involved in drug discovery to deliver more outcomes for less inputs and drug discovery companies are being contracted to undertake activities which would previously be the domain of their clients.

But how hard can logistics for clinical trials be?

A manufacturer ships drugs to investigator sites around the world, where a local doctor administers them to the trial participants and records what happens. That sounds as simple as ordering test tubes from the internet. The logistics magazine SCM World stated that only 39% of pharmaceutical companies see supply chain management as part of their business success.

However, there are other things that need to be considered e.g. the safe return of unused medicines, deliveries of patient samples to central laboratories for analysis, storage conditions for medicines prior to administration can range from monitored ambient 15 – 25 °C to liquid nitrogen at – 150 °C. Not to mention evidence of supply chain integrity and the safe disposal of medicines which can’t be used following an unacceptable temperature excursion during transit.

As with other areas of “just in time”, direct-to-patient shipments are growing in popularity as are those where test data is captured from the patient via a wearable or smartphone device rather than, or in addition to, a clinician. Additionally, clinical trials are taking place in a greater number of locations with different regulatory regimes.

So how can those involved in research ensure that their processes are as cost-effective as possible, while ensuring that the medicine gets to the participant in the right quality and dosage in order to provide them with the most appropriate data for the development of their product?

If you’re involved in drug discovery or contract research please come along to find out more.

Event Programme

17:30 – 18:00 Registration with tea/coffee

18:00 – 18:10 Welcome from Dave Russell-Graham -Inward Investment Manager, Life Sciences and Healthcare, Invest ESSEX

18:10– 18:30 Emirates at Stansted, Phillippa Rose – Senior Sales Executive – Corporate, Emirates

18:30 – 18:50 Tim Davies – Business Development Manager A4P Bio

18:50 – 19:10 Speaker to be named – Biocair

19:10 – 19:30 Questions and Answers/Discussion

19:30 – 20:30 Networking over drinks and canapes

Admission is free of charge but please click here to register on the Eventbrite link.